ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Rating of “Buy” by Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has earned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $21.00.

Several equities research analysts recently commented on the company. Piper Sandler dropped their price objective on ALX Oncology from $48.00 to $8.00 and set an “overweight” rating on the stock in a research report on Friday, August 11th. HC Wainwright reduced their price target on shares of ALX Oncology from $30.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, August 11th. Finally, Cantor Fitzgerald dropped their target price on shares of ALX Oncology from $22.00 to $18.00 and set an “overweight” rating on the stock in a report on Friday, August 11th.

Insiders Place Their Bets

In other news, CAO Shelly Pinto sold 7,345 shares of the business’s stock in a transaction on Thursday, July 6th. The shares were sold at an average price of $6.52, for a total transaction of $47,889.40. Following the completion of the sale, the chief accounting officer now owns 55,713 shares of the company’s stock, valued at approximately $363,248.76. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last ninety days, insiders have sold 13,511 shares of company stock worth $93,148. Company insiders own 50.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ALXO. Braidwell LP lifted its holdings in ALX Oncology by 383.9% during the first quarter. Braidwell LP now owns 1,249,900 shares of the company’s stock valued at $5,650,000 after purchasing an additional 991,620 shares in the last quarter. State Street Corp lifted its stake in shares of ALX Oncology by 47.9% during the 1st quarter. State Street Corp now owns 2,133,744 shares of the company’s stock valued at $36,060,000 after buying an additional 691,410 shares in the last quarter. Millennium Management LLC boosted its holdings in ALX Oncology by 1,161.4% in the 2nd quarter. Millennium Management LLC now owns 429,280 shares of the company’s stock worth $3,473,000 after buying an additional 395,248 shares during the period. ExodusPoint Capital Management LP purchased a new stake in ALX Oncology in the 2nd quarter worth $1,515,000. Finally, Bank of America Corp DE raised its holdings in ALX Oncology by 814.5% during the fourth quarter. Bank of America Corp DE now owns 203,074 shares of the company’s stock valued at $2,289,000 after acquiring an additional 180,868 shares during the period. 83.37% of the stock is currently owned by institutional investors.

ALX Oncology Stock Up 6.1 %

NASDAQ:ALXO opened at $4.52 on Tuesday. The firm has a 50-day simple moving average of $5.78 and a two-hundred day simple moving average of $6.10. The firm has a market cap of $186.01 million, a P/E ratio of -1.41 and a beta of 1.72. ALX Oncology has a fifty-two week low of $3.94 and a fifty-two week high of $13.97. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.49 and a current ratio of 12.49.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings data on Thursday, August 10th. The company reported ($0.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.01. Analysts predict that ALX Oncology will post -3.16 earnings per share for the current fiscal year.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer.